Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura

This publication has 12 references indexed in Scilit:

• Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura
  Blood, 2001
• Treatment of refractory autoimmune haemolytic anaemia with anti‐cd20 (rituximab)
  British Journal of Haematology, 2001
• Sustained remission of platelet counts following monoclonal anti‐CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia
  European Journal of Haematology, 2001
• Current topic: Idiopathic thrombocytopenic purpura
  Archives of Disease in Childhood, 2000
• Anti-CD20 Chimeric Monoclonal Antibody Treatment of Refractory Immune-Mediated Thrombocytopenia in a Patient with Chronic Graft-versus-Host Disease
  Annals of Internal Medicine, 2000
• Elective Splenectomy in Children With Idiopathic Thrombocytopenic Purpura
  Journal of Pediatric Hematology/Oncology, 2000
• Treatment options for chronic immune (idiopathic) thrombocytopenia purpura in children
  Seminars in Hematology, 2000
• Major hemorrhage in children with idiopathic thrombocytopenic purpura: Immediate response to therapy and long-term outcome
  The Journal of Pediatrics, 1998
• Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
  Journal of Clinical Oncology, 1998
• Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology [see comments]
  Blood, 1996